Agios Pharmaceuticals Inc. (NASDAQ: AGIO) plans to submit a supplemental new drug application for mitapivat in sickle cell disease following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE